EPI-001, an androgen receptor (AR) antagonist-like prostate cancer treatment drug developed by Essa Pharma (Figure 11a), can block the transactivation of the AR N-terminal domain (AR-NTD). This evidence concerns the gene AR and prostate carcinoma.